Header Logo

Connection

Patrick Arbuthnot to Hepatitis B virus

Back to Details
This is a "connection" page, showing publications Patrick Arbuthnot has written about Hepatitis B virus.
Patrick Arbuthnot
Connection Strength
13,317
Hepatitis B virus
  1. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets. 2021 06; 25(6):451-466.
    View in: PubMed
    Score: 0,638
  2. Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors. Methods Mol Biol. 2020; 2115:185-197.
    View in: PubMed
    Score: 0,583
  3. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019 Sep 12; 19(1):802.
    View in: PubMed
    Score: 0,571
  4. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep. 2017 08 07; 7(1):7401.
    View in: PubMed
    Score: 0,494
  5. A T7 Endonuclease I Assay to Detect Talen-Mediated Targeted Mutation of HBV cccDNA. Methods Mol Biol. 2017; 1540:85-95.
    View in: PubMed
    Score: 0,474
  6. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 2016 12; 16(12):1517-1527.
    View in: PubMed
    Score: 0,465
  7. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
    View in: PubMed
    Score: 0,447
  8. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
    View in: PubMed
    Score: 0,432
  9. The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Res. 2016 Jan 02; 212:103-13.
    View in: PubMed
    Score: 0,429
  10. Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci. 2015 Jul 31; 16(8):17589-610.
    View in: PubMed
    Score: 0,429
  11. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. J Control Release. 2015 Jul 10; 209:198-206.
    View in: PubMed
    Score: 0,422
  12. Recent advances in use of gene therapy to treat hepatitis B virus infection. Adv Exp Med Biol. 2015; 848:31-49.
    View in: PubMed
    Score: 0,412
  13. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
    View in: PubMed
    Score: 0,407
  14. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,396
  15. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther. 2014; 19(4):363-73.
    View in: PubMed
    Score: 0,383
  16. Recent advances in developing nucleic acid-based HBV therapy. Future Microbiol. 2013 Nov; 8(11):1489-504.
    View in: PubMed
    Score: 0,380
  17. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
    View in: PubMed
    Score: 0,373
  18. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. Bioorg Med Chem. 2013 Oct 15; 21(20):6145-55.
    View in: PubMed
    Score: 0,368
  19. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna. 2012; 1(1):19-25.
    View in: PubMed
    Score: 0,335
  20. Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol. 2011 Nov; 21(6):383-96.
    View in: PubMed
    Score: 0,328
  21. tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochem Biophys Res Commun. 2010 Aug 06; 398(4):640-6.
    View in: PubMed
    Score: 0,302
  22. Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun. 2009 Nov 20; 389(3):484-9.
    View in: PubMed
    Score: 0,285
  23. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009 Jul; 37(13):e91.
    View in: PubMed
    Score: 0,280
  24. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 2008 Nov; 19(11):1325-31.
    View in: PubMed
    Score: 0,269
  25. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008 Jun; 16(6):1105-12.
    View in: PubMed
    Score: 0,259
  26. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 2007 Mar; 15(3):534-41.
    View in: PubMed
    Score: 0,237
  27. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors. Oligonucleotides. 2007; 17(1):104-12.
    View in: PubMed
    Score: 0,237
  28. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
    View in: PubMed
    Score: 0,220
  29. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int. 2005 Feb; 25(1):9-15.
    View in: PubMed
    Score: 0,207
  30. Regulatory elements of hepatitis B virus transcription. J Viral Hepat. 2002 Sep; 9(5):323-31.
    View in: PubMed
    Score: 0,175
  31. Hepatitis B Virus Research in South Africa. Viruses. 2022 08 31; 14(9).
    View in: PubMed
    Score: 0,175
  32. Diversity of Dysregulated Long Non-Coding RNAs in HBV-Related Hepatocellular Carcinoma. Front Immunol. 2022; 13:834650.
    View in: PubMed
    Score: 0,168
  33. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,166
  34. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
    View in: PubMed
    Score: 0,162
  35. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 2001 Apr; 82(2):77-100.
    View in: PubMed
    Score: 0,159
  36. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Curr Opin HIV AIDS. 2020 05; 15(3):200-207.
    View in: PubMed
    Score: 0,149
  37. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun. 2000 Feb 24; 268(3):728-33.
    View in: PubMed
    Score: 0,147
  38. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.
    View in: PubMed
    Score: 0,146
  39. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2018 01 15; 244:311-320.
    View in: PubMed
    Score: 0,119
  40. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochem Biophys Res Commun. 2016 09 30; 478(4):1563-8.
    View in: PubMed
    Score: 0,116
  41. Hepatic Delivery of Artificial Micro RNAs Using Helper-Dependent Adenoviral Vectors. Methods Mol Biol. 2016; 1364:249-60.
    View in: PubMed
    Score: 0,111
  42. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm. 2009 May-Jun; 6(3):706-17.
    View in: PubMed
    Score: 0,070
  43. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat. 2007 Jul; 14(7):447-59.
    View in: PubMed
    Score: 0,061
  44. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology. 2007 Jun; 45(6):1390-9.
    View in: PubMed
    Score: 0,061
  45. Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes (Basel). 2022 10 25; 13(11).
    View in: PubMed
    Score: 0,044
  46. Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia. 2002 Jul-Aug; 4(4):355-68.
    View in: PubMed
    Score: 0,043
  47. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J. 2021 12 13; 18(1):247.
    View in: PubMed
    Score: 0,042
  48. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol. 2021 Jun 21; 27(23):3182-3207.
    View in: PubMed
    Score: 0,040
  49. Site-directed mutagenesis by fusion of contiguous DNA fragments. Biotechniques. 1999 Mar; 26(3):382-4, 386.
    View in: PubMed
    Score: 0,034
  50. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg Med Chem. 2012 Feb 15; 20(4):1594-606.
    View in: PubMed
    Score: 0,021
  51. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010 Apr 19; 143(2):222-32.
    View in: PubMed
    Score: 0,018
  52. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene. 2006 Feb 16; 25(7):1008-17.
    View in: PubMed
    Score: 0,014
  53. Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 2003 May-Jun; 5(3):229-44.
    View in: PubMed
    Score: 0,011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.